PA
GRNA

Parallel Advisors’s GreenLight Biosciences Holdings, PBC Common Stock GRNA Stock Holding History

Parallel Advisors’s Portfolio GRNA Stock Details GRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-347
Closed -$1K – 3576
2022
Q3 		$1K Buy
+347
New +$908 ﹤0.01% 3084

Other funds holding GRNA

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
CGC
Continental Grain Company New York $366M AUM 0.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tao Capital Management San Francisco, California $119M AUM 87.46% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parallel Advisors's GRNA Position: Q4 2022 in Review

Parallel Advisors sold out of GreenLight Biosciences Holdings, PBC Common Stock (GRNA) in Q4 2022, closing a stake of 347 shares — an estimated $1K sold.

Parallel Advisors first reported a position in GRNA in Q3 2022 and held it in 1 quarter. The position peaked at $1K in Q3 2022. 60 funds tracked by Wall St. Rank hold GRNA as of Q4 2022.

  • Parallel Advisors reported no remaining GreenLight Biosciences Holdings, PBC Common Stock position as of Q4 2022 after selling out during the quarter.
  • Parallel Advisors sold 347 GreenLight Biosciences Holdings, PBC Common Stock shares in Q4 2022, an estimated $1K.
  • Parallel Advisors first reported a position in GreenLight Biosciences Holdings, PBC Common Stock in Q3 2022 and held it in 1 quarter.
  • Parallel Advisors's GreenLight Biosciences Holdings, PBC Common Stock position peaked at $1K in Q3 2022.
  • 60 funds tracked by Wall St. Rank held GreenLight Biosciences Holdings, PBC Common Stock as of Q4 2022.

Based on Parallel Advisors's 13F filing for Q4 2022, filed 6 Feb 2023.